Ranibizumab biosimilar is under clinical development by Shanghai Biomabs Pharmaceuticals and currently in Phase I for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase I drugs for Wet (Neovascular / Exudative) Macular Degeneration have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ranibizumab biosimilar overview
Ranibizumab biosimilar (CMAB818) is under development for the treatment of wet age-related macular degeneration. It is administered through intravitreal route. The drug candidate acts by targeting vascular endothelial growth factor A (VEGFA).
Shanghai Biomabs Pharmaceuticals overview
Shanghai Biomabs Pharmaceuticals is a pharamceutical company which is involved in providing medical services and drug development. The company is headquartered in Shanghai, China.
For a complete picture of Ranibizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
